A carregar...
P53-Based Strategy for Protection of Bone Marrow from Y-90 Ibritumomab Tiuxetan
PURPOSE: The main drawbacks of radioimmunotherapy have been severe hematological toxicity and potential development of myelodysplastic syndrome and secondary leukemia. p53 activation is a major pathway by which normal tissues respond to DNA damaging agents such as chemotherapy and radiotherapy, resu...
Na minha lista:
| Publicado no: | Int J Radiat Oncol Biol Phys |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4509863/ https://ncbi.nlm.nih.gov/pubmed/26025778 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijrobp.2015.04.003 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|